References
- Makino S. Progressive fibrosing interstitial lung diseases: a new concept and indication of nintedanib. Modern Rheumatology/the Japan Rheumatism Association. 2021;31: 13–19. doi:10.1080/14397595.2020.1826665
- Gagliardi M, Berg DV, Heylen C-E, Koenig S, Hoton D, Tamirou F, et al. Real-life prevalence of progressive fibrosing interstitial lung diseases. Scientific Reports. 2021;11: 23988. doi:10.1038/s41598-021-03481-8
- Albera C, Verri G, Sciarrone F, Sitia E, Mangiapia M, Solidoro P. Progressive fibrosing interstitial lung diseases: a current perspective. Biomedicines. 2021;9: 1237. doi:10.3390/biomedicines9091237
- Althobiani MA, Russell AM, Jacob J, Ranjan Y, Folarin AA, Hurst JR, et al. Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Frontiers in Medicine. 2024;11: 1296890. doi:10.3389/fmed.2024.1296890
- Antoine MH, Mlika M. Interstitial Lung Disease [Internet]. Bethesda (MD): StatPearls; 2023 [updated 2023; accessed 2024 July 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541084
- Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory Research. 2019;20: 13. doi:10.1186/s12931-019-0980-7
- Vonk MC, Walker UA, Volkmann ER, Kreuter M, Johnson SR, Allanore Y. Natural variability in the disease course of SSc-ILD: implications for treatment. European Respiratory Review. 2021;30: 200340. doi:10.1183/16000617.0340-2020
- Qiu M, Nian X, Pang L, Yu P, Zou S. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: a systematic review and meta-analysis. International Journal of Rheumatic Diseases. 2021;24: 1449–1459. doi:10.1111/1756-185X.14206
- Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. American Journal of Respiratory and Critical Care Medicine. 2020;201: 650–660. doi:10.1164/rccm.201903-0563CI
- Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. European Respiratory Journal. 2020;55: 1902026. doi:10.1183/13993003.02026-2019
- Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clinical Epidemiology. 2019;11: 257–273. doi:10.2147/CLEP.S191418
- Fan Y, Bender S, Shi W, Zoz D. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. Journal of Managed Care & Specialty Pharmacy. 2020;26: 1539–1547. doi:10.18553/jmcp.2020.20136
- Khanna D, Distler O, Cottin V, Brown KK, Chung L, Goldin JG, et al. Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. Journal of Scleroderma and Related Disorders. 2022;7: 168–178. doi:10.1177/23971983211064463
- Hoffmann-Vold AM, Fretheim H, Halse AK, Seip M, Bitter H, Wallenius M, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. American Journal of Respiratory and Critical Care Medicine. 2019;200: 1258–1266. doi:10.1164/rccm.201903-0486OC
- Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Annals of the Rheumatic Diseases. 2021;80: 219–227. doi:10.1136/annrheumdis-2020-217455
- Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. The Lancet. Rheumatology. 2020;2: e71–e83. doi:10.1016/S2665-9913(19)30144-4
- Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. New England Journal of Medicine. 2019;380: 2518–2528. doi:10.1056/NEJMoa1903076
- Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Annals of the Rheumatic Diseases. 2020;79: 1478–1484. doi:10.1136/annrheumdis-2020-217331
- Bendstrup E, Wuyts W, Alfaro T, Chaudhuri N, Cornelissen R, Kreuter M, et al. Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events. Respiration; International Review of Thoracic Diseases. 2019;97: 173–184. doi:10.1159/000495046
- Proesmans VLJ, Drent M, Elfferich MDP, Wijnen PAHM, Jessurun NT, Bast A. Self-reported gastrointestinal side effects of antifibrotic drugs in Dutch idiopathic pulmonary fibrosis patients. Lung. 2019;197: 551–558. doi:10.1007/s00408-019-00260-1
- Cui Y, Zhang M, Leng C, Blokzijl T, Jansen BH, Dijkstra G, et al. Pirfenidone inhibits cell proliferation and collagen I production of primary human intestinal fibroblasts. Cells. 2020;9: 775. doi:10.3390/cells9030775
- Roofeh D, Distler O, Allanore Y, Denton CP, Khanna D. Treatment of systemic sclerosis–associated interstitial lung disease: lessons from clinical trials. Journal of Scleroderma and Related Disorders. 2020;5: 61–71. doi:10.1177/2397198320903208
- Roofeh D, Jaafar S, Vummidi D, Khanna D. Management of systemic sclerosis-associated interstitial lung disease. Current Opinion in Rheumatology. 2019;31: 241–249. doi:10.1097/BOR.0000000000000592